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Background: Genomic analyses of hundreds of prostate tumors have defined a diverse landscape of mutations and
genome rearrangements, but the transcriptomic effect of this complexity is less well understood, particularly at the
individual tumor level. We selected a cohort of 25 high-risk prostate tumors, representing the lethal phenotype, and
applied deep RNA-sequencing and matched whole genome sequencing, followed by detailed molecular
characterization.
Results: Ten tumors were exposed to neo-adjuvant hormone therapy and expressed marked evidence of therapy
response in all except one extreme case, which demonstrated early resistance via apparent neuroendocrine
transdifferentiation. We observe high inter-tumor heterogeneity, including unique sets of outlier transcripts in each
tumor. Interestingly, outlier expression converged on druggable cellular pathways associated with cell cycle progression,
translational control or immune regulation, suggesting distinct contemporary pathway affinity and a mechanism
of tumor stratification. We characterize hundreds of novel fusion transcripts, including a high frequency of ETS
fusions associated with complex genome rearrangements and the disruption of tumor suppressors. Remarkably,
several tumors express unique but potentially-oncogenic non-ETS fusions, which may contribute to the phenotype
of individual tumors, and have significance for disease progression. Finally, one ETS-negative tumor has a striking
tandem duplication genotype which appears to be highly aggressive and present at low recurrence in ETS-negative
prostate cancer, suggestive of a novel molecular subtype.
Conclusions: The multitude of rare genomic and transcriptomic events detected in a high-risk tumor cohort offer
novel opportunities for personalized oncology and their convergence on key pathways and functions has broad
implications for precision medicine.Background
In recent years the application of next-generation sequen-
cing to hundreds of prostate tumors has defined novel
molecular subtypes and characterized extensive genomic
aberration underlying disease initiation and progression
[1,2]. Rearrangements of ETS transcription factors define
approximately 50% of tumors [3], while mutations in the
E3 ubiquitin ligase adapter SPOP and/or disruption to* Correspondence: ccollins@prostatecentre.com
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unless otherwise stated.CHD1, a chromatin remodeling factor, have been reported
in approximately 20% of tumors [4-6]. Both ETS rear-
rangements and SPOP mutations appear to be early events
in prostate cancer development and proceed to influence
the nature of future aberration, resulting in subtype-
specific patterns of downstream genome rearrangement
[6]. However, the glut of genomic and epigenomic aberra-
tions accrued during progression continue to converge on
characteristic ‘prostate cancer pathways’ with scant regard
to molecular subtype: ultimately leading to a highly heteroge-
neous transcriptomic landscape, centered on an overactive
androgen receptor (AR) signaling axis. This heterogeneitytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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nomograms for patient prognostication and to accurately
stratify tumors for precision medicine. Furthermore, since
driver mechanisms within individual prostate tumors are
highly diverse (as evidenced by lack of highly recurrent
mutations), specific events are in many tumors likely to be
unique.
High-risk clinically localized prostate cancer, a poten-
tially lethal disease, is diagnosed in up to one-quarter of
patients [7], and tends to be highly rearranged at the
genomic level, harboring multiple drivers [8]. Since pre-
vious sequence-based studies have focused predomin-
antly on the genome or exome, we hypothesized that
detailed transcriptome dissection of high-risk prostate
tumors will reveal unique and contemporary driver aber-
ration. In this study we characterized the transcriptomes
of 25 high-risk primary prostate tumors including 10 neo-
adjuvant treated tumors, identifying novel gene expression
signatures and hundreds of fusion transcripts, some of
which may be therapeutically tractable. Although highly
heterogeneous, aberration converged on distinct cancer
pathways and functions, with impact for future efforts to
stratify patients for precision medicine. Finally we identi-
fied a previously unrecognized tandem duplicator geno-
type in ETS-rearrangement negative prostate cancer.
Results
Evidence of therapy response and resistance in neo-
adjuvant treated tumors
We performed deep transcriptome sequencing (median
711× coverage), shallow whole genome sequencing (median
23× coverage), and aCGH copy number profiling on 25
high-risk primary prostate tumors, five matched adjacent-
benign prostate tissues, and a patient-derived xenograft
(PDX) originating from a needle biopsy of high-risk pri-
mary disease (Figure 1A; Additional file 1: Tables S1-3).
Detailed follow-up information for more than 2 years was
present for all but two patients: the majority of patients
(20/25) had a PSA recurrence or never reached PSA nadir,
and eight of these have so far progressed with distant me-
tastases, emphasizing the selected high-risk nature of the
cohort.
Ten tumors were exposed to neo-adjuvant hormone
therapy (NHT) for 1 to 9 months, and global transcript
profiling demonstrated a marked split between these sam-
ples and the untreated (hormone-naïve) tumors (Figure 1B;
Additional file 1: Table S4; Additional file 2: Figure S1). Sig-
nificantly downregulated genes in NHT tumours (DESeq
comparison; Benjamini-Hochberg P <0.05) were typically
androgen responsive (for example, TMPRSS2, KLK3,
BMPR1B, TPD52) or steroidogenesis-related (for example,
DHCR24, SCD), consistent with a reduction in androgen
receptor activity (Figure 1C; Additional file 1: Table S5;
Additional file 3: Text S1). This effect is in stark contrastto the frequent observation of AR reactivation in
castration-resistant prostate cancer; which is often
concomitant with the overexpression of de novo steroido-
genic enzymes [9]. Upregulated genes in NHT tumors
were linked to growth suppression and increased apop-
tosis (for example, DUSP2, DUSP4, CCDC8, TNS4) and
also with cytotoxic T lymphocytes (for example, CD8A,
GZMK), with the latter in line with previous reports dem-
onstrating an increase in prostatic infiltration of lympho-
cytes post-hormone treatment [10,11]. However, although
the data suggested that most tumors were responding to
androgen deprivation therapy at the time of tumor collec-
tion, four tumors displayed elevated CHGA expression at
the mRNA level (Figure 1D). CHGA is a marker of NEPC:
an aggressive anaplastic subtype that is very rare at diagno-
sis but may emerge after long term androgen deprivation
[12]. NEPC cells are AR-negative and are thought to arise
via ‘transdifferentiation’ from AR-positive adenocarcinoma
cells [13]. Elevated CHGA mRNA expression is of unclear
significance in three of the four positive tumors since they
exhibited <10% CHGA positive cells by immunohisto-
chemistry (Figure 1E-G). However, one tumor (T20) ex-
hibited widespread CHGA positivity, and morphology
distinctive of neuroendocrine prostate cancer (NEPC)
(Figure 1H). Dual immunohistochemistry for AR and
CHGA on the same patient’s diagnostic biopsy (prior
to NHT; diagnosis of adenocarcinoma, Gleason 4 + 5)
revealed that biopsy contained few CHGA positive
cells, while the prostatectomy sample (after 8 months
of goserelin and flutamide) harbored few AR positive
foci (Figure 1H, Additional file 2: Figure S2). Although
we cannot exclude biopsy sampling bias, FISH on the
prostatectomy sample confirmed the presence of the
androgen-driven TMPRSS2-ERG rearrangement, sug-
gesting an adenocarcinoma origin for the NEPC com-
ponent within tumor T20 and the potential that this
therapy resistant tumor was driven (at least in part) by
NHT treatment (Figure 1; Additional file 2: Figure S2;
Additional file 3: Text S1) [14-17].
Outlier gene expression suggests contemporary tumor-
dependent pathway affinity
Despite elucidation of distinct molecular subtypes, the
transcriptomic diversity of adenocarcinoma at prostatec-
tomy is high, due in part to the protracted natural history
of tumor development and the varying temporal relevance
of a range of rare driver events. Concordantly, we did not
observe broad gene expression differences between all
tumor and benign samples at the significance levels used
for the NHT comparisons described above (DESeq com-
parison; Benjamini-Hochberg P <0.05) (Additional file 1:
Table S4). Nevertheless, the contemporary reliance (that
is, at the time of sample collection) of individual tumors
on particular cellular functions or signaling pathways for
Figure 1 Therapy response and resistance in neo-adjuvant hormone treated tumors. (A) Breakdown of the patient cohort. (B) Principal
component analysis using RNA-seq derived transcript expression (after removal of three outliers; see Additional file 2: Figure S1) demonstrating
the global split between hormone-naive tumors and tumors treated with neo-adjuvant hormone therapy (NHT). (C) Representative genes that
were significantly differentially expressed between hormone-naive and NHT tumors (DESeq comparison; Benjamini-Hochberg corrected P values).
(D) Expression levels of the neuroendocrine prostate cancer marker CHGA in the cohort, showing elevated levels in NHT tumors. † indicates the
unique hybrid adenocarcinoma-neuroendocrine tumor described in-depth in a separate study (ref 45). (E-G) CHGA protein staining showing
diffuse positivity (<10% of cells overall) in selected NHT tumors with elevated CHGA mRNA expression levels. (H) Dual AR (brown) and CHGA
(pink) staining in tumor T20 (with the highest mRNA expression of CHGA in (D)) showing evidence of neuroendocrine transdifferentiation,
potentially in response to 8 months of NHT. The top panel shows the diagnostic biopsy, prior to treatment, showing few (pink) CHGA positive
cells but predominant (brown) AR staining, while the bottom panel shows tumor T20 (at radical prostatectomy (RP)), demonstrating small cell
morphology, widespread (pink) CHGA positivity and scant remaining AR positive foci.
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level. Therefore, to capture inter-tumor differences and
similarities in pathway affinity, and to take advantage of
the high dynamic range and absolute quantification inherent
of RNA-seq data, we identified genes in each tumor
that were expressed at an outlier level in that tumorand no more than one-third of the cohort (median out-
lier transcripts per sample = 437; Additional file 1:
Table S6). This ‘recurrent’ outlier analysis allowed the
detection of individual-specific outliers, and those that
are more frequent. Remarkably, the outlier genes of 17/25
tumors showed significant enrichment (Benjamini-Hochberg
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(Figure 2; Additional file 1: Tables S7 and S8).
Three main ‘clusters’ of pathway enrichment emerged
(Figure 2). Pathways associated with cell cycle progres-
sion (for example, Mitotic Roles of Polo-Like Kinase)
were significantly enriched in six samples, potentially in-
dicating a subset of tumors with elevated proliferation
rates: a claim further substantiated by high Ki67 indicesFigure 2 Significant pathway enrichment of transcripts with outlier g
enrichment scores for representative canonical pathways in each tumor sam
different tumors converge on distinct cellular functions (pathway score = -l
(that is, B-H <0.1) are shown). Note pathway names truncated from 1Role o
Damage Checkpoint Regulation, 3Role of Pattern Recognition Receptors in
in Rheumatoid Arthritis. The bottom panel provides explorations of several
genes within those pathways across the entire tumor cohort (full list of outlie
Tumors with outlier gene enrichment within a given pathway are repres
Ki67 indices in three tumors reflecting the probable high proliferation ra
pathways (for additional images with larger fields see Additional file 2: Fin these tumors (Figure 2; Additional file 2: Figure S3).
Enrichment was driven by the upregulation of several
key regulators of the cell cycle, including PLK1, CDC25A,
and CDK1, genes known to be associated with aggressive
tumors, and with inhibitors in various stages of clinical
development [18-20]. The translational control pathway
‘EIF2 Signaling’ was enriched in four tumors, with three-
quarters also overexpressing genes involved in ‘mTORene expression. The heatmap in the top panel provides the pathway
ple and benign tissue showing that outlier transcript sets from
og10(Benjamini–Hochberg adjusted P value); only pathway scores >1
f CHK Proteins in Cell Cycle Checkpoint Control, 2Cell Cycle: G2/M DNA
Recognition of Bacteria and Viruses, 4Altered T Cell and B Cell Signaling
key pathways, highlighting the expression distribution of representative
r gene sets within enriched pathways in Additional file 1: Table S8).
ented by colored circles. Immunohistochemistry images show high
te of tumors with outlier gene enrichment within cell cycle-related
igure S3).
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in prostate cancer [21]. This enrichment was caused in
part by the upregulation of a range of ribosomal genes, a
species frequently overexpressed in cancer [22]. Although
increased ribosomal gene transcription may simply reflect
a cell with higher proliferation, ribosomal biogenesis can
itself be a driver of cell cycle progression, and several
prominent oncogenes mediate their effects via the ribo-
some [22]. Interestingly, tumors with outlier gene enrich-
ment in EIF2/mTOR also overexpressed genes related to
mitochondrial dysfunction, and the tumor (T23) with the
most significant enrichment in these three pathways had
outlier expression of AKT1 (notable since mitochondrial
respiration defects can lead to the activation of AKT-
mediated survival [23]; Additional file 2: Figure S3). Fur-
thermore, T23 also demonstrated striking enrichment in
the ‘Glycolysis I’ pathway, including marked upregulation
of the Warburg-effect facilitator PKM2 (evidence of coor-
dinated regulation of this pathway was similarly evident in
public data (Additional file 2: Figure S3)). Finally, a third
group of tumors demonstrated enrichment of outlier gene
expression within pathways associated with the immune
system. Four of these tumors were exposed to NHT and
distinct patches of infiltrating lymphocyte populations
were evident by histology (Additional file 2: Figure S4).
Accordingly, these samples had high expression of B cell
markers (for example, CD79, CD19, BLK) and/or toll-like
receptors (for example, TLR1), as well as T cell markers
such as CD4, CD8A, and CD3A. Nevertheless, two tumors
within the ‘immune group’ were untreated (T19 and T24)
and although T19 had high expression of T and B cell
markers, T24 had scant evidence of a significant popu-
lation of invading lymphocytes either by histology or mRNA
expression of immune cell markers (Additional file 2:
Figure S4). High, unique expression of chemokines includ-
ing CXCL1, CXCL5, and IL8 in this tumor may therefore
have tumor cell origins. Furthermore, it is worth noting
that outlier genes from the five adjacent benign samples
did not show enrichment in any of the three pathway clus-
ters defined above, including benign samples matched to
two tumors with high immune enrichment (Figure 2).
Since only two patients had died at time of writing, we
evaluated instead the biochemical recurrence-free sur-
vival of different pathway groups. Despite the fact that
the entire cohort was high-risk, the eight patients in the
cell cycle and translation/metabolism groups fared sig-
nificantly worse than all other patients (P = 0.0009; log
rank test) (Additional file 2: Figure S5). Overall, these
data promise a strategy to classify tumors based on con-
temporary druggable pathway affinity, which if corrobo-
rated in larger RNA sequence cohorts in the future, has
potential to compliment patient stratification for precision
medicine and provide insight into the functional conse-
quences of heterogeneity.High frequency of ETS fusions, complex rearrangements,
and disruption to tumor suppressors
DNA rearrangement is a hallmark of prostate cancer, caus-
ing distinctive chromosomal copy number alterations
and creating oncogenic fusion genes [1]. Sentinel work
over the past decade has defined the landscape of recur-
rent fusion genes in prostate cancer as limited to ETS
gene rearrangements in approximately 50% of tumors,
and rare (approximately 1%) rearrangement to RAF kinase
family members [24]. However, non-recurrent events have
attracted less attention, but may still have significant rele-
vance within specific tumors. Indeed, genome breakpoints
are likely to be an underestimated mutational mechanism
in prostate cancer as they appear to be enriched within
tumor suppressor genes, but analyses are complicated by
the large number of passenger events (prostate tumors
frequently harbor hundreds of genome rearrangements),
and the false positives that are inevitable when predicting
genomic events. Therefore, we focused our rearrangement
analyses on our deep transcriptome data, since theoretic-
ally only genome breakpoints occurring within gene loci
will be detectable and exon-exon junctions are less likely
to cause mapping issues. We hypothesized that disrupted
genes would tend to fall in prostate cancer-related path-
ways and that a fraction of non-recurrent fusion genes
would have oncogenic potential.
Using an integrated approach involving the fusion gene
prediction tool deFuse [25], gene expression profiles and
genome copy number data we identified 242 fusion tran-
scripts arising from genome rearrangement in the 25 pa-
tient tumors and the PDX tumor (validation of 75 novel
fusion transcripts was performed by PCR and Sanger se-
quencing; validation rate >95% [72/75]; Additional file 1:
Table S9). Twenty-three out of 26 tumors expressed ≥1 fu-
sion, at an average burden of 11 fusion transcripts. The
majority (18/26; 69%) were positive for an ETS gene re-
arrangement (15 ERG, 4 ETV1; Figure 3A; Additional file 2:
Figure S6); and ERG fusion junction read counts corre-
lated with ERG gene expression (r = 0.82). Given the
recent characterization of high frequency complex re-
arrangements (also termed ‘chromoplexy’) in prostate
tumors [6], we searched for evidence that fusion genes
were involved in complex rearrangements including >2
genome breakpoints. Despite shallower DNA sequence
data, 210/242 fusions were evaluable (expressed in tumors
with paired DNA sequence coverage >5×) for involvement
in complex rearrangements, and we could identify DNA
breakpoints for 169 (80%; Additional file 1: Table S9).
There were 37 separate complex rearrangements involving
83/210 fusion transcripts (validation rate 100% [13/13];
Figure 3A-F; Additional file 1: Table S10), with 16 tumors
containing ≥1 complex rearrangement. Of 17 evaluable
ETS fusions, 14 were present in a complex rearrangement,
and ETS rearrangements were involved in 38% (14/37) of
Figure 3 The landscape of non-ETS fusion genes and complex genome rearrangements in high-risk prostate cancer. (A) Depicts the
number of expressed fusion genes (‘Fusion load’) and complex genome rearrangements (‘Complex’) detected in each tumor sample, and
indicates selected genes involved in fusion events. Only genes with putative links to cancer are shown (full list of involved genes in Additional file
1: Table S9). Genes marked with * indicates a putative gain-of-function. † highly complex chromothripsis-driven rearrangements; ‡ involvement in
complex rearrangement but not expressed; § DNA sequence coverage too low to elucidate complex rearrangements. (B) Schematic of the
complex genome rearrangement (also known as chromoplexy [6]) in tumor T20 which lead to the disruption of TP53. Breakpoints in the six genes
involved are indicated on the left, together with the final configuration on the right. This particular rearrangement led to the expression of just
one fusion transcript (i.e. MATR3-HMG3P22). (C-F) Further schematics of complex genome rearrangements (C) shows the same rearrangement as
(B)]. Green nodes indicate a gene is disrupted by rearrangement while red and gray indicate potential activating or neutral effects, respectively.
Full edges represent a DNA rearrangement, and dotted lines indicate a rearrangement that was also detected in the RNA sequence data (that is,
a fusion transcript was expressed). (G) Schematics of selected fusion genes with putative gain-of-function. Tumor ID is provided in each box, and
major protein domains are annotated.
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with a significant NEPC component was positive for
both ERG and ETV1 rearrangements (by RNA sequen-
cing and PCR validation); raising the possibility of
multi-focal ‘collision’ cancers where only the ERG rear-
ranged cells ‘transdifferentiated’ into NEPC (discussed
further in Additional file 3: Text S1).
The majority of fusion genes were likely to result in
loss-of-function of one or both partners through inter-
ruption and/or truncation of the coding sequence. In 18tumors fusion gene events caused disruption to known
or putative tumor suppressor genes, including genes as-
sociated with TP53 apoptosis (for example, TP53 in four
tumors; PPP1R13B), MAPK p38 apoptosis (for example,
MAP3K5), cell cycle progression (for example, RB1,CCND3),
DNA damage response (for example, MRE11A), and
DNA architecture (for example, PDS5A) (Figure 3A;
Additional file 1: Table S9). Indeed, using Ingenuity Path-
way Analysis, the top canonical pathway enriched by the
344 unique fusion partners (that mapped to a protein
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(Benjamini-Hochberg corrected P = 3.4 × 10-5) and the
top disease/bio function was ‘Cancer: Solid Tumor’
(Benjamini-Hochberg corrected P = 1.66 × 10-10). Other
classes of rearranged genes included E3 ubiquitin ligases
and members of eukaryotic translation initiation com-
plexes (Figure 3A). Particularly notable within the latter
was disruption to EIF4E3, a gene residing within a gen-
ome rearrangement hotspot on chromosome 3p13 har-
boring three context-specific tumor suppressors FOXP1,
RYBP, SHQ1 [8,26]. EIF4E3 falls in between FOXP1 and
RYBP, and is itself a purported tumor suppressor [27].
Although 3p13 is deleted in approximately 20% of pros-
tate tumors, there is an enrichment of 3p13 deletions in
ERG positive tumors [26]. Our data suggest this associ-
ation may be partly underpinned by complex genome
rearrangement, since two tumors appeared to have dis-
ruption to 3p14 simultaneously to ERG rearrangement
(complex rearrangements in tumor T1 (EIF4E3) and
tumor T19 (FOXP1); Figure 3E and F).
Expression of non-ETS in-frame fusion genes
We searched for evidence of non-ETS fusions which
could be oncogenic. Approximately 60 fusion genes were
predicted to have an open reading frame across the fusion
junction, while 45 were associated with outlier expression
of the 3’ gene (Additional file 1: Table S9). Several can-
didates had theoretical gain-of-function (Figure 3G;
Additional file 1: Table S9; Additional file 2: Figure S6),
including genes within intracellular signaling cascades
(for example, WNT or PI3K pathways). For example, a
PDS5A-KLB fusion (tumor T4) led to 10-fold overex-
pression of a truncated, but in-frame, KLB transcript.
KLB (beta-Klotho) is a tissue restricted single-pass trans-
membrane protein that acts a co-receptor for FGF family
members and has been implicated in prostate cancer
[28,29]. Expression of KLB in T4 is driven by PDS5A, a
known tumor suppressor involved in DNA repair and sis-
ter chromatid cohesion, disruption of which may also con-
fer a selective benefit. METAP2-PIK3C2G in tumor
T17 resulted in the seven-fold upregulation of in-frame
PIK3C2G, while FARS2-BMP6 in tumor T9 may also be
relevant since BMP6 is linked to invasion of prostate
cancer cells [30]. The PDX LTL311 expressed a ZNF618-
MUSK fusion transcript resulting in the expression of a
transcript coding for the protein kinase domain of MUSK,
a muscle-specific receptor tyrosine kinase that is not nor-
mally expressed in prostate.
Genes involved in cell cycle regulation were also po-
tentially activated, including in hormone-naïve tumor
T22 where a fusion was associated with six-fold overex-
pression of tyrosine phosphatase CDC25C. In LTL311
the ubiquitously expressed EHMT1 likely drove overex-
pression of ANAPC2. ANAPC2 is a component of theanaphase promoting complex/cyclosome (APC/C), a cell
cycle-regulated E3 ubiquitin ligase that controls progression
through mitosis and the G1 phase of the cell cycle. Interest-
ingly, the partners of ANAPC2, CDC20 and CDH1, were
also upregulated in this tumor (Additional file 2: Figure S6),
and APC/C has a recently-documented important role
in cancer, and can be inhibited with a small molecule
(Tosyl-L-Arginine Methyl Ester). Another oncogenic ubi-
quitin ligase, UBE3A (aka E6-AP; marks TP53 for prote-
olysis degradation) was placed under control of the AR
via fusion to the first exon of androgen responsive gene
SLC45A3 in T11, although UBE3A was not expressed at
an outlier level in this tumor at the time of prostatec-
tomy. Tumor T11 had an intact TP53 gene, but examin-
ation of copy number and mutation data (Additional file 2:
Figure S6 and Additional file 3: Text S1) revealed that
TP53 was disrupted in over half of the high-risk cohort
(Additional file 2: Figure S7).
A recurrent tandem duplication genotype in prostate
cancer
The two tumors expressing the greatest number of fusion
genes were ETS negative (tumor T4 and LTL311; also
SPOP wild type), consistent with Baca et al.’s work dem-
onstrating a higher frequency of genome rearrangement
in this tumor subtype compared to ETS positive tumors
[6]. Remarkably, in the hormone-naïve tumor T4 all 25
expressed fusion genes were intra-chromosomal, and were
predicted to have arisen through individual tandem dupli-
cation events. The copy number profile of T4 was unchar-
acteristic of prostate cancer, replete with hundreds of focal
gains (Figure 4A). Overlapping focal copy gains with gen-
ome rearrangement predictions revealed an additional 216
tandem duplications spread across the entire genome of
T4 (241 in total; validation rate 100% (13/13)) (Figure 4B;
Additional file 1: Table S11). Several tandem duplication
events had potential to contribute to cancer in T4, most
notably the non-ETS fusion gene PDS5A-KLB (described
above), and a high focal genome amplification of the
MDM2 gene loci (Figure 4C). The latter was caused by
serial tandem duplication events across a roughly 3 Mb
region of chromosome 12 (confirmed by CISH in
Figure 4E and F). MDM2 is an oncogenic ubiquitin ligase
whose action leads to the degradation of TP53 (similar to
UBE3A). MDM2 was expressed very highly at the mRNA
level in T4, and may counteract the intact TP53 gene in
this tumor (Figure 4D). This is particularly intriguing in
the context of the UBE3A fusion gene described above, as
it conceivably represents a distinct mechanism of TP53
control in prostate tumors and suggests therapeutic strat-
egies which relieve ubiquitin-mediated TP53 repression
may have efficacy [31,32].
The prostate cancer copy number ‘signature’ of 8p loss
and 8q gain was still present in tumor T4, but overlaid
Figure 4 A tandem duplication genotype in high-risk prostate cancer. (A) Copy number profile of hormone-naïve tumor T4, showing focal
gains across the entire genome, distinctive of tandem duplications. Key events discussed in the text are annotated. (B) Schematic illustrating how
individual tandem duplications present at the genomic level. (C) Serial tandem duplications across the MDM2 loci in T4. The copy number plot
shows a focal high gain, with the colored lines representing segments that have been duplicated. Tandem duplication ID is indicated next to
each colored line and in brackets is the estimated number of copies of each tandem duplication. For example, the genetic breakpoint of the most
focal tandem duplication (green line) was detectable at a high frequency indicating multiple copies, suggesting that the breakpoint itself had
been subsequently duplicated, potentially by the broader tandem duplications (pink and blue lines). Note that one breakpoint (purple line) was
predicted at <1 suggestive of sub-clonality and highlighting the potential for continual evolution. (D) Transcript expression of MDM2 across the
high-risk cohort showing elevated expression in tumor T4 relative to the other tumors and benign samples. (E, F) Chromogenic in situ
hybridization of MDM2 in benign tissue (E) and tumor (F) from T4 confirming MDM2 amplification. Note the ‘clumps’ of staining in the tumor cells
suggesting MDM2 amplifications are proximally located (consistent with tandem duplication). (G) Copy number profiles from two tumors in a
public dataset, which appear to harbor the distinctive pattern of focal gains across the entire genome (see Additional file 2: Figure S9 for further
examples). Oncogenes within focal amplifications are annotated.
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points of several tandem duplications were detectable only
at sub-clonal levels (Figure 4C; Additional file 2: Figure S8)
and had reduced copy number peaks relative to other
gains. Together with the (serially-generated) amplification
peaks of MDM2 and NRP2, these data suggest that the
tandem duplication genotype arose over time rather than
in a single catastrophic event (c.f. chromothripsis [33]),
and that there may be a specific susceptibility to tandem
duplication in T4.Interestingly, the genotype of T4 appears highly similar
to a recently reported ‘tandem duplicator’ genotype in
ovarian and breast cancer [34,35], raising the possibility
of a pan-cancer mechanism, and recurrence beyond this
singleton case in prostate cancer. Therefore, we searched
for evidence of similar cases in two external cohorts of
copy number profiles from localized and metastatic
prostate tumors [5,8]. Although categorical detection of
tandem duplications is not possible from copy number
data alone, we identified five tumor profiles with tens to
Wyatt et al. Genome Biology 2014, 15:426 Page 9 of 14
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T4 (Figure 4G; Additional file 2: Figure S9). Furthermore,
it is of note that the five prostate tumors putatively identi-
fied with the tandem duplication genotype were ETS
rearrangement negative, CHD1 wild-type, and where
genotyping was carried out, SPOP wild-type (tumor T4
was also CHD1 and SPOP wild-type). As such it is
probable that the tandem duplicator genotype is recurrent
at low frequency in prostate tumors and may in fact com-
prise a distinct molecular class.
Discussion
We have characterized the transcriptomic landscape of
25 high-risk prostate tumors. Focus on non-recurrent
aberration revealed considerable inter-tumor heterogeneity,
and a diverse range of novel potentially-driving fusion
genes and outlier transcript expression signatures, some of
which may be therapeutically exploitable. Non-recurrent
events still converged on distinct cancer-related functions
and pathways, a finding assuming increased significance
given the advent of precision medicine and a renewed mo-
tivation for accurate patient stratification.
We identified a tandem duplication genotype in the
ETS-negative tumor T4 that appears to be recurrent at a
low level in prostate, breast, and ovarian cancers. In T4,
tandem duplications resulted in several potentially driv-
ing events via oncogene amplification (for example,
MDM2, NRP2), gene fusion (for example, PDS5A-KLB),
or tumor suppressor disruption (for example, EP300).
Inhibitors for MDM2 (and to a lesser extent NRP2) are
in pre-clinical development [36,37], but the presence of
multiple tandem duplications at sub-clonal proportions
in T4 indicates a propensity for evolution in response to
targeted therapy. The suggestion that tandem duplications
are arising over multiple cell cycles helps distinguish the
genotype from chromothripsis and chromoplexy, which
are thought to occur in a single event, and are typically as-
sociated at the copy number level with multiple deletions
(rather than focal gains) [6,33]. Evidence of recurrence of
the tandem duplication genotype at low frequency in other
prostate tumors, as well as in recent studies of breast and
ovarian tumors [34,35] suggests the possibility of a com-
mon cause, probably in defective DNA maintenance [38].
Interestingly, prostate tumors with evidence of the tandem
duplication genotype were all ETS and CHD1 wild type,
hinting at a distinct and novel molecular subtype. This hy-
pothesis requires rapid confirmation in additional tumors,
since the evident aggression of the genotype demands an
early detection strategy.
Several high-risk tumors expressed unique, but poten-
tially functional, non-ETS fusions. Non-ETS fusion tran-
scripts have been previously identified in prostate
tumors [39-41], but have been understudied due to their
non-recurrence, and the predicted loss-of-function ofthe vast majority. Their clinical relevance requires fur-
ther elucidation, and much will be revealed through
transcriptome sequencing of advanced prostate tumors
underway as part of the SU2C Dream Team efforts.
However, it is interesting to speculate that the lack of
androgen responsive promoters for the majority of po-
tentially functional non-ETS rearrangements identified
here may confer a benefit when under the stress of an-
drogen blockade. Although the lower depth of our DNA
sequencing precluded precise clonality estimates, several
of the potentially functional fusions had read counts
suggestive of sub-clonality, and it will be interesting to
monitor whether they will be preferentially selected or
lost over the course of disease. It may ultimately become
possible to therapeutically exploit unique fusions such as
those identified here, but in the near future non-ETS fu-
sions have potential to complement patient stratification
for precision medicine (for example, fusion of a PI3K
subunit could imply stronger rationale for pathway in-
hibition). In parallel to the patient sequence cohort, we
identified several potentially functional fusion genes in
the ETS-negative PDX LTL311. This xenograft tumor
was derived from a needle biopsy specimen obtained at
diagnosis [13], and given the protracted disease course
of prostate cancer it is therefore conceivable that target
discovery and in vivo testing of personalized therapies
is possible very early in disease course, at least for the
highest risk cases.
The inability to determine whether a given aberration
has historical or contemporary significance is a major
drawback of genome-centric studies. However, as ap-
propriate patient selection rapidly becomes a necessity
for clinical trial design, it is imperative that we under-
stand contemporary dependence on oncogenic or drug-
gable pathways. Studies of outlier gene expression can
give insight into contemporary drivers, and has consid-
erable precedence in prostate cancer (for example, dis-
covery of ETS fusions and SPINK1 subtype [42]), but
the high dynamic range and absolute quantification
afforded by transcriptome sequencing offers new oppor-
tunities not available to previous microarray-based ap-
proaches. In our study, we revealed highly statistically
significant enrichment of outlier gene expression within
distinct cellular pathways associated with metabolism,
translation, cell cycle, and the immune system. These
associations may reflect differing pathway reliance of in-
dividual tumors and therefore a rationale for discrete
therapeutic strategies (for example, mTOR inhibition),
although further functional studies are clearly required.
Interestingly, where comparisons to matched benign tissue
were possible, outlier gene pathway enrichment appeared
to be specific to the tumor foci, even the immune-related
pathways where one might assume lymphocyte infiltration
to be prostate-wide. Some outlier gene signatures, such as
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expression of specific chemokines, were detected in just a
single tumor, highlighting both the remarkable diversity of
gene usage, and the requirement for further characterization
of individual tumor transcriptomes.
The logistical challenge of obtaining longitudinal tumor
samples in patients with prostate cancer has long ham-
pered research into therapy resistance. Although the ap-
plication of ‘liquid biopsies’ to late-stage patients will
undoubtedly reveal novel mechanisms of resistance, the
study of neo-adjuvant treated primary tumors has proven
to be a partial solution, leading for example to the discov-
ery of the adaptive stress-response as an effective drug
target [43]. Our study revealed a marked therapy effect
in the 10 NHT tumors, and evidence of early drug re-
sistance in one tumor (T20) via probable transdifferen-
tiation of adenocarcinoma to neuroendocrine prostate
cancer (NEPC). We recently reported a patient-derived
xenograft model of primary adenocarcinoma which upon
androgen ablation rapidly ‘transdifferentiates’ to complete
NEPC via an adaptive response [13]. It seems likely that
this is the situation in tumor T20, and underscores the ur-
gent need to develop better biomarkers to monitor for
early resistance.
Conclusions
Through the first deep transcriptome sequencing study
of prostate tumors we have revealed surprising levels of
inter-tumor heterogeneity converging on key functions
and pathways, and conferring significant implications for
precision medicine. Our study emphasizes the value of
focusing on the individual rather than the cohort, espe-
cially when profiling extreme phenotypes, since we iden-
tified a diverse range of novel potentially-driving fusion
genes, outlier transcript expression signatures and an ag-
gressive tandem duplicator genotype.
Methods
Sample collection and sequencing
Prostate tissue was collected from high-risk patients
undergoing radical prostatectomy and snap frozen ac-
cording to the current Vancouver General Hospital path-
ology protocol. All patients signed a formal consent
form approved by the ethics board, and in accordance
with the Helsinki Declaration. High-risk cases were se-
lected for this study by meeting any of the following cri-
teria: Gleason ≥8, PSA ≥20, or clinical stage T3a and
above. Hematoxylin and eosin (H&E) stained FFPE and
frozen sections were reviewed by an expert pathologist
(LF) to identify blocks with highest tumor content. For each
frozen block used, a 5 μm slide was first taken for H&E
staining, then 4 × 100 μm sections were taken for DNA and
RNA isolation, before a second 5 μm slide was taken for
H&E staining. Each H&E slide was required to have tumorcontent >50% in order for a tumor to proceed for se-
quencing. Additionally, we included the patient-derived
xenograft LTL311 in our sequencing cohort. LTL311 is
derived from a needle biopsy of high-risk primary adeno-
carcinoma [13]. This tumor was included in the study to
evaluate the suitability of modelling high-risk disease from
biopsy tissue prior to prostatectomy.
For DNA isolation, digestion of 100 μm snap-frozen
tumour tissue with 0.2 mg/mL Proteinase K (Roche) in
digestion buffer (50 mM NaCl, 10 mM Tris-HCl (pH 8.3),
1 mM EDTA and 0.5% SDS) was carried out overnight at
55°C. Samples were incubated with RNase solution at
37°C for 30 min and treated with protein precipitation
solution followed by isopropanol precipitation of the
DNA. The DNA was further purified by Phenol:Chloro-
form:Isoamyl Alcohol (25:24:1), and precipitated by adding
1/10th volume of 3 M sodium acetate and 2.5 volumes of
100% ethanol, before re-suspension in TE. RNA from
snap-frozen tissue was isolated using the mirVana Isola-
tion Kit from Ambion (AM 1560). DNA and RNA se-
quencing was performed on Illumina HiSeq 2000 at
BCCA Michael Smith Genome Sciences Centre according
to standard protocols. Four high-risk tumors sequenced
on GAII in a previous study [44,45] were re-sequenced on
HiSeq 2000 for this study.
Array comparative genomic hybridization copy number
profiling
A total of 0.5 μg of each genomic DNA was fluorescently
labeled by following the NimbleGen enzymatic labeling
protocol which employs Cy3 and Cy5 labeled random
nanomers (TriLink Biotechnologies), a heat fragmentation
step at 98°C for 10 min, and amplification with Klenow
fragment 5′-3′exo- (New England Biolabs). Five micro-
grams of each Cy5-labeled sample was co-hybridized with
5 μg of Cy3-labeled human male reference DNA (Pro-
mega Corp) on Agilent SurePrint G3 Human Catalog
CGH 8 × 60 K or 4 × 180 k slides following the Agilent
Oligonucleotide Array-Based CGH for Genomic DNA
Analysis Protocol v6.2. Arrays were scanned with the
Agilent DNA Microarray Scanner, and quantified with
Feature Extraction 10.5.1.1. CGH processed signal was
uploaded into Biodiscovery Nexus CGH software v7,
where quality was assessed and data were visualized and
analyzed. Data is available at GEO accession number
GSE55016.
Sequence data mapping and processing
Raw sequence data are available at The European Nucleo-
tide Archive (ENA), accession number PRJEB6530. DNA-
seq reads were aligned onto the human reference genome
(hg19/GRCh37) using BWA (0.5.9-r16) [46] allowing 1 nt
mismatch at most in a 24 nt seed. For RNA-seq, reads
were mapped onto the hg19 genome and exon-exon
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known gene model annotation from Ensembl release 62.
Reads with an unmapped mate or multi-mapped location
were filtered out using Bamtools [48] and PCR or sequen-
cing optical duplicates were marked and removed by Pic-
ard [49]. Using NCBI dbSNP build 132, multiple sequence
local realignment around InDels and base quality recali-
bration was performed by GATK (The Genome Analysis
Toolkit) [50] to correct likely misalignments. For DNA
and RNA sequencing data of all specimens, SNVs/InDels
were identified and filtered by GATK [51] to achieve
high-confidence sites (strand bias, base quality, mapping
quality, and position bias were taken into account).
Additionally for RNA-seq data, we used samtools [52]
to call SNVs/InDels, and retained as high-confidence
only those sites which were concordant between both
GATK and samtools results. All variants were annotated
with genic regions and potential consequences on protein-
coding sequences using the tool AnnoVar [53]. The effect
of non-synonymous SNVs on protein function was assessed
using Condel [54], a method which integrates several pre-
dictive tools (for example, SIFT, Polyphen2, MutationAsses-
sor). To prioritize variants we first filtered against dbSNP
build 137 (non-flagged only) and the five adjacent benign
samples sequenced in this study, and then only considered
variants detectable in both DNA and RNA reads (that is,
expressed variants). Finally we excluded identical variants
concurrently predicted in more than two samples as likely
artefact. Mutated genes present in either Cosmic Cancer
Gene Consensus [55] or reported to be a ‘Mut-Driver
Gene’ [56] are shown in Additional file 2: Figure S10 and
Additional file 1: Table S12. Mutation frequency was cal-
culated based on DNA-seq reads alone. Reads of reference
and variant were counted after local realignment and du-
plicate removal.
Based on the alignment of RNA-seq reads, gene expres-
sion profiles for each sample were calculated based on the
gene annotation (Ensembl release 62). Only reads which
were unique to one gene and exactly corresponded to
gene structure were assigned to the corresponding genes.
Raw read counts were normalized by R package DESeq
[57], which was designed for gene expression analysis of
RNA-seq data across all samples. Transcript expression
profiles for all samples are provided in Additional file 1:
Table S4. DESeq was also used to compare transcript ex-
pression between neo-adjuvant treated and hormone
naïve tumors (after exclusion of the two tumors with
NEPC components (tumors T16 and T20)), using a
Benjamini-Hochberg corrected P value. To detect outlier
gene expression across the cohort we used the Generalized
Extreme Studentized Deviate (ESD) test [58] with an upper
bound of 15 (half of the cohort size). Additionally, in order
to filter out background noise and minimize artifact detec-
tion, we calculated the average background noise for eachsample based on the coverage of inter-genic and intronic
regions (which should be largely absent from pure RNA-
sequence data). After subtracting background noise, we
required that an upregulated outlier gene have a sequence
depth greater than 10X, while for a downregulated outlier
gene, the average sequence depth of non-outliers must
also be greater than 10X. Pathway and functional enrich-
ment analyses of outlier genes was performed using the
Ingenuity Knowledge Base (Ingenuity Systems [59]).
Identification of fusion genes and genome
rearrangements
We used the deFuse algorithm [25] to predict rearrange-
ments in RNA sequence libraries. Since there were ap-
proximately 8,000 unfiltered defuse predictions of chimeric
RNAs after analyses of the 31 RNA sequence libraries
(Additional file 4: Table S13), we filtered predictions ac-
cording to the following criteria: a fusion gene candidate:
(1) must be predicted to have arisen from genome re-
arrangement, rather than via a readthrough event; (2) must
be predicted in no more than two sequence libraries (with
the exception of ETS fusions; this step removes recurrent
artifacts); (3) must map unambiguously on both sides of
the predicted breakpoints (that is, no multi-mapping
reads); (4) must not map entirely to repetitive elements;
(5) must be detected in >5 reads (either split or spanning).
This step reduced predicted fusion genes to <1,000, and
candidates were then further prioritized by fulfilling any of
the following secondary criteria: mapping to edge of copy
number aberration, differential exon expression either
side of breakpoints; outlier expression of 3′ gene in that
sample relative to others. Although this stringent filter-
ing strategy has potential to remove some true positives,
we felt that preferable to an elevated false discovery rate.
To identify complex genome rearrangements underlying
predicted fusion RNAs we applied the nFuse pipeline
[60] to RNA and DNA sequence libraries. Validation
was performed by PCR across the predicted fusion junc-
tions in cDNA or gDNA (oligonucleotide sequences
provided in Additional file 1: Table S9 and S10). All ampli-
fication products were sequenced with an ABI PRISM 310
Genetic Analyzer to confirm identity.
Immunohistochemistry
Immunohistochemical staining was conducted on serial
sections (5 μm thick) by Ventana autostainer model Dis-
cover XT TM (Ventana Medical System) with enzyme la-
beled biotin streptavidin system and solvent resistant DAB
Map kit by using 1/50 of CHGA rabbit monoclonal anti-
body # AC-0037 (Epitomics, Inc.), 1/200 concentration of
AR (N-20) antibody # SC-816 (Santa Cruz Biotechnology),
and 1/500 of anti-Ki-67 rabbit monoclonal antibody clone
SP6 (Thermo Scientific™ Lab Vision). For dual staining a
Blue Map kit was used with 1/500 of CHGA mouse
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1/50 concentration of AR (N-20) antibody cat # SC-816
(Santa Cruz Biotechnology). For negative controls the
primary antibodies were replaced with the correspond-
ing species normal immunoglobulin G. Previously tested
tissue samples from our tumor bank were used as posi-
tive controls.
Chromogenic in situ hybridization (CISH) was carried
out using the Ventana discovery ultra-automated slide
stainer two color method. After standard pre-treatment
of formalin-fixed, paraffin-embedded human prostate
cancer specimen, the tissues were subjected to protease
digestion for 8 min, followed by incubation with an
MDM2 DNP labelled DNA probe and a Chromosome
12 DIG labelled DNA probe for 6 h. Detection was car-
ried out with Ventana’s ultraView SISH DNP Detection
Kit and Red ISH DIG Detection Kit. Finally the slides
were counterstained with Hematoxylin II and blueing re-
agent. Fluorescence in situ hybridization (FISH) for ERG
gene rearrangement was carried out using a previously
documented protocol [61] and scored manually by an ex-
pert pathologist (RM).Additional files
Additional file 1: Tables S1-S12.
Additional file 2: Figures S1-S10.
Additional file 3: Text S1.
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